Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 7/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 7/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.74 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11710419 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL13014950 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL14619144 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL972352 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL13589886 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL11487059 | 0.83 | OPRD1 (0.71) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL18408052 | 0.82 | OPRM1 (0.70) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL2909939 | 0.82 | OPRM1 (0.70) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL1206232 | 0.82 | OPRM1 (0.70) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 | |
| SCHEMBL12894697 | 0.81 | OPRM1 (0.68) | SIGMAR1OPRM1OPRD1OPRK1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288596-B1 | ALICYCLIC CARBOXYLIC ACID DERIVATIVES OF BENZOMORPHANS AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2016-11-30 | — | — | EP | disclosed |
| US-9073870-B2 | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-8765780-B2 | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20140179669-A1 | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20110269791-A1 | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179669-A1 | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use | HSD11B1, CYP11B1, CYP46A1 | SIGMAR1 723/4885OPRM1 175/4885OPRD1 96/4885 |
| US-20110269791-A1 | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use | HSD11B1, CYP46A1, HSD11B2 | SIGMAR1 878/4885OPRM1 235/4885OPRD1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.